Health AI Central
Peer-Reviewed Publication
Clin Chim Acta2027;592121229.January 1, 2027Journal Article

NT-IGFBP-4: A novel biomarker for risk prediction in acute heart failure.

Ling Li1, Jing Wang2, Chen Chen1, Yu Wu1, Juan Yang1, Xin Shu3, Litao Zhang3, Yi Zhang4, Zhenlu Zhang5
1Clinical Laboratory, Wuhan Asia Heart Hospital, Wuhan 430022, China.
2Immunoassay Reagent R&D Department, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Shenzhen 518107, China.
3Clinical Laboratory, Wuhan Asia General Hospital, Wuhan 430022, China.
4Immunoassay Reagent R&D Department, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Shenzhen 518107, China. Electronic address: zhangyi_b@mindray.com.
5Clinical Laboratory, Wuhan Asia Heart Hospital, Wuhan 430022, China. Electronic address: zhenluzhangwh@163.com.
PubMed DOI

Abstract

OBJECTIVES: Insulin-like growth factor binding protein-4 (IGFBP-4) fragments generated by PAPP-A-mediated proteolysis are emerging biomarkers of myocardial stress and remodeling. Although elevated N-terminal IGFBP-4 (NT-IGFBP-4) has been associated with heart failure (HF), its prognostic value remains unclear. This study evaluated the prognostic performance of NT-IGFBP-4, measured using a validate…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.